Rheumatology: application experience of mycophenolate mofetil in adolescent idiopathic inflammatory myopathy

Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in the treatment of juvenile idiopathic inflammatory myopathy (JIIM.

Methods: Patients diagnosed with JIIM and treated with MMF at the Juvenile Dermatomyositis Study Group (JDRG) in the United Kingdom or the Giannina Gaslini Institute in Genoa, Italy were included in the stud.

The following information was collected retrospectively at MMF initiation, 3, 6, 12 months after treatment initiation and at last follow-up: clinical presentation, laboratory data, physician's subjective assessment of disease activity, standardized outcome measures of muscle strength/endurance , skin disease activity, physical function, overall disease activity, cumulative damage, and ongoing treatmen.

Results: Of the 29 patients, 23 had juvenile dermatomyositis and 6 had overlapping myositi.

The number of patients without active disease increased from 13% at baseline to 65% at last follow-u.

Conclusions: This study demonstrates that MMF is a valuable therapeutic option for the management of JII.

Source:

Varnier GC, Consolaro A, Cheng IL, et a.